<DOC>
	<DOCNO>NCT00802919</DOCNO>
	<brief_summary>This 12-week double-blind placebo control parallel group study efficacy varenicline ( Chantix ) smoke cessation schizophrenic patient , effect cognitive function patient schizophrenia . Correlations make biological predictor efficacy : ) measure nicotinic receptor lymphocytes b ) DNMT1 GAD67 mRNA lymphocyte . Subjects current cigarette smoker hsitory regular smoker .</brief_summary>
	<brief_title>Varenicline Cognitive Deficits Cigarette Smoking Schizophrenia - Efficacy Predictors</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Cognition Disorders</mesh_term>
	<mesh_term>Varenicline</mesh_term>
	<criteria>Diagnosis Schizophrenia Schizoaffective Disorder Current Cigarette Smoker Age 1865 Currently take antipsychotic medication prior history hospitalization acute myocardial infarction stroke , persistent angina pectoris current symptom Patients previously try varenicline stop take sideeffects severe nausea vomit suicide attempt last year prominent serious suicidal thought past year Women pregnant , nursing , unable use reliable contraception significant renal impairment ( Creatinine â‰¥ 1.5 ) baseline Hamilton Depression Scores &gt; 20</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>schizophrenia</keyword>
	<keyword>smoking</keyword>
	<keyword>nicotine</keyword>
	<keyword>cognitive deficit</keyword>
	<keyword>DNMT1 mRNA</keyword>
	<keyword>nicotinic receptor</keyword>
	<keyword>Cognitive Deficits Schizophrenia</keyword>
</DOC>